Business Context and Reporting Period
Company: ADC Therapeutics SA
Filing Type: Form 8-K (Current Report)
Date of Report: June 3, 2026
Event: Announcement of topline data from the Phase 3 LOTIS-5 confirmatory trial for ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Key Financial Metrics
This filing is a Current Report (8-K) focused on clinical trial results and does not contain audited financial statements, revenue figures, profit margins, cash flow data, or specific debt balances. The text references the Company's expected cash runway into at least 2028 and mentions indebtedness facilities with HealthCare Royalty Management, Blue Owl, and Oaktree, but does not provide specific numerical values for these items.
Material Changes and Clinical Results
The primary material event is the successful completion of the LOTIS-5 trial primary endpoint. Key comparative data versus the control arm (R-GemOx) includes:
- Progression-Free Survival (PFS): Met primary endpoint with statistical significance (HR = 0.73; p-value = 0.008). Median PFS was 6.1 months (ZYNLONTA + rituximab) vs. 4.7 months (R-GemOx).
- Overall Survival (OS): No detrimental effect observed (HR = 0.96), though impacted by higher switching rates in the control arm.
- Response Rates: Overall Response Rate (ORR) was 58.1% vs. 45.2%; Complete Response (CR) rate was 39.5% vs. 26.7%.
- Duration of Response: Median DOR was 9.2 months vs. 7.7 months; Median Duration of CRs was 16.8 months vs. 12.3 months.
- Long-term CR: 48.5% of patients achieving CR remained in CR at 24 months vs. 16.7% in the control arm.
- Safety Profile: Higher rates of serious adverse events (49.0% vs. 34.5%) and Grade 5 TEAEs (13.2% vs. 4.6%) were observed in the ZYNLONTA arm. Grade 5 events were predominantly in patients aged 75 years or older.
Guidance, Outlook, and Risks
Regulatory Path: The Company plans a pre-Supplemental Biologics License Application (sBLA) meeting with the FDA in August 2026 and intends to submit the sBLA in the fourth quarter of 2026.
Strategic Actions: Management is evaluating value-maximizing alternatives, including near-term cost reduction initiatives.
Risks and Uncertainties: Forward-looking statements highlight risks regarding the adequacy of data for full regulatory approval, the benefit-risk profile of ZYNLONTA, the ability to maintain accelerated approval, and the impact of indebtedness terms. Specific risks include the outcome of FDA meetings, potential restrictions on activities due to debt agreements, and uncertainties in international trade policies.
Investor Verification Checklist
- Verify the specific terms and covenants of the Company's indebtedness with HealthCare Royalty Management, Blue Owl, and Oaktree to assess liquidity constraints.
- Confirm the Company's actual cash runway and burn rate to validate the "into at least 2028" projection.
- Monitor the outcome of the planned pre-sBLA meeting with the FDA in August 2026 for any regulatory hurdles.
- Review the detailed safety data regarding Grade 5 TEAEs in patients aged 75+ to understand potential label restrictions.
- Assess the impact of the announced cost reduction initiatives on future operational expenses and R&D timelines.